Portal de Periódicos da CAPES

Chronic Hepatitis B Monitoring and Treatment Patterns in Five European Countries with Different Access and Reimbursement Policies

2013; SAGE Publishing; Volume: 19; Issue: 3 Linguagem: Inglês

10.3851/imp2719

2040-2058

Victoria Aramă, Hakan Leblebicioğlu, Krzysztof Simon, Jean Pierre Zarski, Claus Niederau, François Habersetzer, Johannes Vermehren, Wiesława Błudzin, Mariana Jinga, Sercan Ulusoy, Isabelle Klauck, Edith Morais, Stefan Bjork, Bénédicte Lescrauwaet, Driss Kamar, S Zeuzem, Patrick Marcellin, Danielle Botta‐Fridlund, Stanislas Pol, M. Travis Maynard, François Habersetzer, Xavier Causse, Laurent Alric, Pauline Simo Noumbissie, Stefan Mauss, Guido Gerken, Tobias Goeser, Manfred Wiese, Heiner Busch, Lothar Schneider, Jens Schubert, Meike Brenner, Inka Scheffrahn, Andrzej Dziambor, Dariusz Goryszewski, Barbara Postawa-Kłosińska, Jerzy Sieklucki, Robert Pleśniak, Monica Acalovschi, C Tănăsescu, Lucian Raducan, Ioan Sporea, M Voiculescu, Olimpia Chira, Sorin Ștefan Aramă, Mihaela Rădulescu, Adriana Nicolau, Doina Nițescu, Daniel Munteanu, Andrei Nanu, Isabel Dan, Diana Nicoliţă, Camelia Ionescu, Monica Ecobici, Gina Micu, Raluca Irinel Parepa, Andra‐Iulia Suceveanu, Gaye Usluer, Mevlüt Başkol, Reşat Özaras, Şaban Esen, Elif Doyuk Kartal, Tansu Yamazhan,

Liver Disease Diagnosis and Treatment

In Europe, health-care policies are determined at a national level and differ between countries. This analysis from a prospective, longitudinal, non-interventional study aimed to describe patterns in the clinical monitoring and treatment of chronic hepatitis B (CHB) in five European countries.Country-specific cohorts of adult patients with compensated CHB managed in clinics in Germany, France, Poland, Romania and Turkey were followed for up to 2 years between March 2008 and December 2010.A total of 1,267 patients were included. Baseline age and gender distribution were similar across countries for patients who were treated (n=567) and untreated (n=700) at baseline. Most treated patients were receiving monotherapy at baseline, most frequently with entecavir or tenofovir in Germany, France and Turkey, and with lamivudine in Poland and Romania. Use of pegylated interferon was more frequent in Poland and Romania than in other countries. In Romania monotherapy with entecavir increased after it became reimbursed in 2008. Hospitalizations during follow-up were more frequent in Romania (1.45 hospital days/patient-year) and Poland (1.81 days/patient-year) than in Turkey, France and Germany (0.00, 0.05 and 0.10 days/patient-year, respectively); clinic visits were more frequent in Poland (3.20 versus 0.30-1.78 visits/patient-year across other countries).These results illustrate country-specific patterns in the management of CHB patients across Europe. Observed monitoring patterns, hospitalization rates and other health-care utilization may be related to cost and reimbursement issues; however, further study in individual countries would be required to confirm these (post hoc) observations.